Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of the study was to evaluate the potential of IFN regulatory factor-1 (IRF-1) for cytokine gene therapy of HCC using an IRF-1/human estrogen receptor fusion protein (IRF-1hER), which is reversibly activatable by beta-estradiol (E2).
|
11289138 |
2001 |
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Expression of IFN-alpha receptors was found in all 3 HCC cell lines.
|
11172336 |
2001 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we show that acyclic retinoid acts synergistically with IFNs in suppressing the growth and inducing apoptosis (as characterized by DNA fragmentation and chromatin condensation) in 5 human HCC cell lines (JHH7, HuH7, PLC/PRF/5, HLE, and HLF).
|
12395321 |
2002 |
Liver carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
During follow-up, two patients of the control group and three patients of the IFN group developed cirrhosis, and one of the IFN- treated patients progressed to hepatocellular carcinoma.
|
16012762 |
2005 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the case of hepatitis C virus (HCV) infection, important characteristics are nonresponsiveness to IFN therapy and development of hepatocellular carcinoma.
|
16322229 |
2005 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
IFN therapy reduces cirrhosis and HCC development.
|
17107734 |
2007 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data identify TRAIL as a novel downstream transcriptional target of PML-mediated apoptosis in hepatomas and suggest that PML and TRAIL play important roles in IFN-regulated apoptosis in HCC.
|
19141642 |
2009 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Of interest, 209A has been associated with IFN resistance and HCC in previous studies.
|
19383824 |
2009 |
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Type I IFN receptor type 2 (IFNAR2) expression correlates significantly with clinical response to interferon (IFN)-alpha/5-fluorouracil (5-FU) combination therapy for hepatocellular carcinoma (HCC).
|
19401692 |
2009 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
IFN-α has janus face of consistently suppressing HCC growth, however, promoting tumor metastasis capacity, which is of clinical indication for the scientific administration of IFN-α and the similar antiangiogenesis drugs for their dual effect on tumor growth and metastasis.
|
20213095 |
2010 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The miR-21 in HCC cell lines and clinical HCC samples is a significant modulator of the anti-tumour effect of IFN-α and 5-FU.
|
20978511 |
2010 |
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Peg-IFN inhibits β-catenin signaling through the up-regulation of RanBP3, which may be a contributory mechanism for the delayed HCC and improved survival in treated HCV patients.
|
21093092 |
2011 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results indicated that miR-146a regulated the sensitivity of HCC cells to the cytotoxic effects of IFN-α through SMAD4, suggesting that this miRNA could be suitable for prediction of the clinical response and potential therapeutic target in HCC patients on IFN-based therapy.
|
21982769 |
2011 |
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We found that while HBV replication in transfected human hepatoma Huh-7 cell was severely inhibited by IFN-α treatment as reported previously, this inhibition was markedly impaired in the cell in which the expression of IFN-inducible, double-stranded RNA-dependent protein kinase (PKR) was stably and specifically suppressed through RNA-interference.
|
21710204 |
2011 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This finding points to a cross-talk between different IFN types and β-catenin signaling pathways which might be carrying a biological effect not only on HCC, but also on processes where the two pathways bridge.
|
23056571 |
2012 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We investigated the antitumor activity of treatment with IFN-α, with the oncolytic adenovirus SG600-IL-24, or the combination of both in HCC in vitro and in vivo.
|
22569271 |
2012 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Maintenance therapy with the use of long-term low-dose PEG-IFNα-2a is effective for preventing HCC occurrence irrespective of the IL28B SNP, at least for a subset of CHC patients.
|
23258095 |
2012 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggest that IFN-α gene-modified NKL cells could be suitable for the future development of cell-based immunotherapeutic strategies for hepatocellular carcinoma.
|
23759701 |
2013 |
Liver carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We genotyped the rs8099917 single-nucleotide polymorphism in 351 hepatitis C-associated HCC patients without history of IFN-based treatment, and correlated the age at onset of HCC in patients with each genotype.
|
23689989 |
2014 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results are as follows: (1) both ETV and TDF showed long-term efficacy and safety; (2) PEG IFN-α resulted in a greater decline in HBV DNA levels and a higher rate of HBeAg seroconversion; (3) combination therapy with IFN plus two analogues did not elevate the rate of sustained responses; (4) both ETV and TDF showed efficacy and safety with cirrhosis (ETV especially displayed efficacy and safety with decompensated cirrhosis), and (5) suppression of HCC was observed by ETV and IFN.
|
26584037 |
2015 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we aim to detect the anti-tumor effect of a novel gene delivery system - IFN-α2b gene-modified human bone marrow mesenchymal stem cells (BMSCs) in HCC.
|
26518164 |
2015 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Emodin also sensitized the antiproliferative effect of IFN-α in HeLa cervical carcinoma cells and reduced tumor growth in Huh7 hepatocellular carcinoma-bearing mice.
|
26683360 |
2016 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Higher IFIT3 expression in HCC tissues predicts better response to IFN-α therapy in HCC patients; IFIT3 promotes IFN-α effector responses and therapeutic effects by strengthening IFN-α effector signaling in HCC.(Hepatology 2017;66:152-166).
|
28295457 |
2017 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, quercetin also sensitized the antiproliferative effect of IFN-α on hepatocellular carcinoma HepG2 and Huh7 cells.
|
29371942 |
2017 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggested that K6G potentiated the inhibitory effect of IFN-α on HCC cell proliferation through activation of the JAK/STAT signaling pathway by inhibiting SOCS3 expression.
|
29031523 |
2017 |